Company Encyclopedia
View More
name
Annovis Bio
ANVS.US
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
1.946 T
ANVS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Annovis Bio to Present Phase 3 Parkinson’s Data at Parkinson Study Group Annual Meeting

    Annovis Bio Inc. will present Phase 3 data on buntanetap's effects in Parkinson’s disease dementia at the 2025 Parkinson Study Group Annual Meeting in San Diego. The presentation, led by CEO Maria Maccecchini, will focus on cognitive outcomes and biomarker improvements. The event is scheduled for December 5 at 6:15 p.m. PST.

    Reuters·
    US
    ANVS
    0.00%
    Reuters·
    US
    ANVS
    0.00%

    Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages

    Annovis Bio, Inc. (NYSE:ANVS) has received a consensus "Hold" rating from five research firms. Analysts have mixed recommendations: one "sell," two "hold," and two "buy." The average 12-month target price is $13.50. Recent insider purchases include shares by Director Michael B. Hoffman and CEO Maria-Luisa Maccecchini. Institutional investors have modified their holdings, with notable activity from Vanguard Group Inc. and JPMorgan Chase & Co. Annovis Bio develops drugs for neurodegenerative diseases, with Buntanetap as its lead product candidate.

    Market Beat·
    US
    ANVS
    0.00%
    Market Beat·
    US
    ANVS
    0.00%

    Annovis Bio Unveils New Clinical Data on Buntanetap at CTAD 2025

    Annovis Bio Inc. will present new clinical data on buntanetap at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The presentations will cover amyloid co-pathology and cognitive decline in Parkinson’s disease dementia patients, and a Phase 3 study on buntanetap's efficacy in Alzheimer’s treatment. The results will be shared at the CTAD conference.

    Reuters·
    US
    ANVS
    0.00%
    Reuters·
    US
    ANVS
    0.00%

    Chmn Hoffman Buys 20,000 ($69.9K) Of Annovis Bio Inc [ANVS]

    Hoffman Michael B Chairman of the Board of Annovis Bio Inc [ANVS] filed a Form 4 on November 21, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/21/25TransactionPurchaseShares20,000Price$3.50Value$69,900Ending Holdings: 2,713,896 (2,490,539 - Direct, 223,357 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ANVS
    0.00%
    Reuters·
    US
    ANVS
    0.00%

    Annovis Bio Inc. Director Michael B. Hoffman Reports Acquisition of Common Shares

    Michael B. Hoffman, Director at Annovis Bio Inc., has reported the acquisition of common shares in the company. This announcement was made through a filing accessible via EDGAR, the U.S. SEC's system. The information is provided by Public Technologies and is intended for informational purposes only.

    Reuters·
    US
    ANVS
    0.00%
    Reuters·
    US
    ANVS
    0.00%
    © 2025 Longbridge｜Disclaimer